David Sinclair Supplement Protocol: What the Science Says

David Sinclair, the Harvard longevity researcher behind the Information Theory of Aging and author of *Lifespan*, has been the most influential voice in popularizing longevity science for a general audience. He has also been unusually transparent about his personal supplement protocol, which has drawn both acclaim and criticism from the scientific community. This guide applies the same evidence standards Everspan uses for all 157 interventions to evaluate each component of his reported stack.

**What Sinclair reportedly takes (as of last public disclosures):** NMN (1g/day), resveratrol (1g/day with yogurt), metformin (1g/day), quercetin and fisetin (occasionally), spermidine, vitamin D3, vitamin K2, aspirin (low-dose), statin (rosuvastatin).

The honest assessment: the lifestyle components of his approach (low-calorie diet, intermittent fasting, plant-heavy foods, exercise) have far stronger evidence than the supplements. The supplements are a bet on mechanisms that have not yet been validated in long-term human longevity trials.

**NMN — The Centerpiece**

NMN (nicotinamide mononucleotide) reliably raises NAD+ levels in blood and tissues — that much is confirmed in human trials (Yoshino 2022, Liao 2021, Kim 2022). NAD+ declines with age and is implicated in mitochondrial function, DNA repair, sirtuin activation, and other aging-relevant pathways. Sinclair's research on sirtuins and NAD+ metabolism is foundational to why NMN attracted this attention.

The critical gap: raising NAD+ in blood does not yet have a proven translation to longevity or functional outcomes in humans. The mouse data is compelling. The human data shows biomarker movement (NAD+ levels, some metabolic markers) but not yet reduced mortality or improved healthspan metrics over long follow-up. NMN gets Grade B− on Everspan's evidence scale — biologically plausible, early human data positive, long-term outcome data absent.

Sinclair takes 1g/day. Studies used 250mg–1,000mg/day. No dose-response established in humans. Taking 500mg/day is reasonable for longevity-motivated adults who understand the evidence gap.

**Resveratrol — The Most Controversial Choice**

Resveratrol is the supplement where Sinclair's research most directly informed his personal protocol and where the human evidence has been most disappointing. The SIRT1 activation story is mechanistically elegant; the translation to human outcomes has not materialized.

Large trials — including the ASPREE-XT resveratrol sub-study — have not shown benefits in aging markers. The CALERIE trial found lifestyle caloric restriction more effective than any resveratrol intervention. A 2023 meta-analysis of resveratrol RCTs found no significant effects on the most relevant aging biomarkers (telomere length, CRP, HbA1c) versus placebo.

Sinclair takes resveratrol with fat (yogurt) — correctly, as this significantly improves absorption. The bioavailability problem is real: without fat co-administration, resveratrol is poorly absorbed. But even with optimal absorption, the human evidence base is weak. Everspan grades resveratrol as Grade C for longevity outcomes — mechanistically interesting, human trial data has not validated animal model findings.

**Metformin — The Most Evidence-Supported but Most Restricted Choice**

Metformin is the most evidence-supported item in the Sinclair protocol and also the one that requires a prescription in most countries. The TAME trial (Targeting Aging with Metformin) — the first FDA-recognized trial with aging itself as an endpoint — is ongoing. Observational data from Type 2 diabetic populations consistently shows metformin users have lower all-cause mortality and lower rates of cancer, cardiovascular disease, and neurodegenerative disease compared to non-metformin-treated diabetics.

The critical nuance Sinclair acknowledges: metformin blunts exercise adaptations. A 2023 NEJM Evidence paper confirmed that metformin partially inhibits the mitochondrial biogenesis response to aerobic exercise — the very adaptations that make exercise so longevity-relevant. For highly active individuals, the exercise interaction is a meaningful trade-off. Sinclair reportedly cycles metformin off on heavy training days.

Metformin is not available OTC. Berberine activates the same AMPK pathway with similar (if somewhat weaker) metabolic effects and no prescription requirement — Grade B evidence for metabolic outcomes.

**Quercetin and Fisetin — Senolytics with Early Evidence**

Senolytics — compounds that selectively clear senescent cells — are one of the most scientifically compelling longevity research areas. Sinclair uses quercetin and fisetin episodically (not daily) as senolytic agents. The human evidence is nascent: small trials suggest senescent cell burden reduction, but no large RCT has confirmed lifespan or healthspan effects in healthy humans.

The intermittent dosing approach (pulsed rather than daily) is consistent with the proposed mechanism — senescent cells accumulate over time, not daily. This protocol is experimental; Everspan grades senolytics as Grade C for longevity in healthy adults.

**Spermidine — Autophagy Induction with Growing Evidence**

Spermidine induces autophagy — the cellular recycling process that declines with aging. Observational studies (the SMiles trial; population data from Austria) suggest higher dietary spermidine correlates with lower cardiovascular mortality. Small intervention trials are positive. Evidence is early-stage; mechanism is sound; Everspan grades it B− with upside as trials mature.

**What Is Well-Supported in the Sinclair Protocol**

Vitamin D3 with K2, low-dose aspirin for selected populations, and statins (if indicated) have strong evidence bases independent of longevity research. These are standard preventive medicine for middle-aged adults, not controversial biohacking.

The dietary approach — plant-heavy, low in saturated fat and processed food, calorie-conscious, with time-restricted eating windows — has the most robust evidence of any component. The Blue Zones literature, PREDIMED-PLUS, and caloric restriction trials all point to diet quality and energy balance as dominant drivers of healthspan.

**How to Approach the Sinclair Protocol Pragmatically**

The intellectually honest framing: Sinclair is running an n=1 experiment on himself, informed by deep mechanistic knowledge, with full awareness that human longevity trial data is decades away. His willingness to be public about his protocol is valuable for the field; it should not be mistaken for validated clinical practice.

For adults motivated to act on the same evidence base: 1. Optimize lifestyle first (Zone 2 cardio, resistance training, sleep, diet) — these have Grade A evidence 2. Add NMN (500mg/day) if NAD+ biology resonates — understand it is a mechanistic bet, not a proven intervention 3. Skip resveratrol — the evidence case has not held up; the money is better spent elsewhere 4. Consider berberine instead of metformin for metabolic AMPK activation (OTC, no prescription needed, less exercise interference) 5. Quercetin and fisetin: reasonable additions for motivated adults — watch for larger senolytic trials in 2025-2026 6. Take vitamin D3/K2, omega-3, magnesium — these have the evidence to support anyone